Shedding Baggage, Alnylam Turns a Corner

What convinces investors that a drug discovery company is likely to bring products to the market, and rewards to shareholders? It comes down to just a few things: Proprietary biology. Confident... Read more »

Genomes-R-Us: Is BGI now Complete?

The sad endgame in the acquisition of Complete Genomics (NASDAQ: GNOM) came last week: having failed to create a sustainable business, CGI was put up for sale in June of... Read more »

Biogen Idec Lets Stromedix Do The Hard Part

For anyone wondering about the value that can be added by entrepreneurs and venture capitalists to the drug discovery and development process, look no further than Stromedix. This venture-backed company... Read more »

Big Pharma Attempts to Extend Own Lifespan by Activating Sirtuins

Can drugs that supposedly “activate” a controversial target—sirtuin proteins—stop or even reverse the aging process? A new report this week said “No.” According to this report, published Wednesday night in Nature ... Read more »

How Google+ Could Transform Healthcare & Medicine

This post was co-authored by Rich Whalley, an associate at CBT Advisors.

What could Google do if it had access to everyone’s health data?

You’re probably already thinking a few things:

1.... Read more »

How Sanofi Could Start Off on the Right Foot in Cambridge

To: Chris Viehbacher, CEO, Sanofi Aventis
From: The Boston Biotech Community
Re: Making the Most of the Impending Merger

Dear Mr. Viehbacher,

In the heat of the discussions regarding... Read more »